China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn
Brief: Izervay® (Avacincaptad Pegol Intravitreal Solution) Demonstrated Increased Probability Of Maintaining Driving Eligibility In Geographic Atrophy Patients
Brief: Astellas Pharma Inc - Notice Regarding Impairment Loss And Extraordinary Losses In Non-Consolidated Financial Results(J-GAAP)
Table: Astellas -2025/26 group results (IFRS)
Table: Astellas -2025/26 parent results
Brief: Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer
Vir Biotech drops after $150 mln stock sale
Vir Biotech soars again after prostate cancer drug collaboration with Astellas
Vir Biotech slips after unveiling $200 mln stock offering plans
Vir Biotechnology soars on Q4 results beat, Astellas collaboration
Brief: Astellas & Vir Biotechnology Collaborate To Advance VIR-5500
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Brief: Evinova Announces Strategic Collaborations With Astellas, Astrazeneca & Bristol Myers Squibb
India's Zydus agrees $120 million settlement with Astellas over bladder drug (updated)
India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment
Brief: Zydus Lifesciences Enters Settlement Agreement With Astellas Over Myrbetriq